Literature DB >> 32620673

Remodeling the epigenome and (epi)cytoskeleton: a new paradigm for co-regulation by methylation.

Cheryl Walker1, Warren Burggren2.   

Abstract

The epigenome determines heritable patterns of gene expression in the absence of changes in DNA sequence. The result is programming of different cellular-, tissue- and organ-specific phenotypes from a single organismic genome. Epigenetic marks that comprise the epigenome (e.g. methylation) are placed upon or removed from chromatin (histones and DNA) to direct the activity of effectors that regulate gene expression and chromatin structure. Recently, the cytoskeleton has been identified as a second target for the cell's epigenetic machinery. Several epigenetic 'readers, writers and erasers' that remodel chromatin have been discovered to also remodel the cytoskeleton, regulating structure and function of microtubules and actin filaments. This points to an emerging paradigm for dual-function remodelers with 'chromatocytoskeletal' activity that can integrate cytoplasmic and nuclear functions. For example, the SET domain-containing 2 methyltransferase (SETD2) has chromatocytoskeletal activity, methylating both histones and microtubules. The SETD2 methyl mark on chromatin is required for efficient DNA repair, and its microtubule methyl mark is required for proper chromosome segregation during mitosis. This unexpected convergence of SETD2 activity on histones and microtubules to maintain genomic stability suggests the intriguing possibility of an expanded role in the cell for chromatocytoskeletal proteins that read, write and erase methyl marks on the cytoskeleton as well as chromatin. Coordinated use of methyl marks to remodel both the epigenome and the (epi)cytoskeleton opens the possibility for integrated regulation (which we refer to as 'epiregulation') of other higher-level functions, such as muscle contraction or learning and memory, and could even have evolutionary implications.
© 2020. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Actin; DMNT; Epigenetics; Epiregulation; SETD2; Tubulin

Mesh:

Substances:

Year:  2020        PMID: 32620673      PMCID: PMC7338266          DOI: 10.1242/jeb.220632

Source DB:  PubMed          Journal:  J Exp Biol        ISSN: 0022-0949            Impact factor:   3.312


  104 in total

1.  Histone methyltransferase SETD3 regulates muscle differentiation.

Authors:  Gwang Hyeon Eom; Kee-Beom Kim; Jin Hee Kim; Ji-Young Kim; Ju-Ryung Kim; Hae Jin Kee; Dong-Wook Kim; Nakwon Choe; Hye-Jeong Park; Hye-Ju Son; Seok-Yong Choi; Hyun Kook; Sang-Beom Seo
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

Review 2.  Epigenetics in comparative biology: why we should pay attention.

Authors:  Warren W Burggren; David Crews
Journal:  Integr Comp Biol       Date:  2014-04-09       Impact factor: 3.326

3.  Quantification of Tau Protein Lysine Methylation in Aging and Alzheimer's Disease.

Authors:  Carol J Huseby; Claire N Hoffman; Grace L Cooper; Jean-Christophe Cocuron; Ana P Alonso; Stefani N Thomas; Austin J Yang; Jeff Kuret
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

4.  Deficiency in DNA methylation increases meiotic crossover rates in euchromatic but not in heterochromatic regions in Arabidopsis.

Authors:  Cathy Melamed-Bessudo; Avraham A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-28       Impact factor: 11.205

Review 5.  Methylation, mutation and cancer.

Authors:  P A Jones; W M Rideout; J C Shen; C H Spruck; Y C Tsai
Journal:  Bioessays       Date:  1992-01       Impact factor: 4.345

Review 6.  Nature, nurture and epigenetics.

Authors:  David Crews; Ross Gillette; Isaac Miller-Crews; Andrea C Gore; Michael K Skinner
Journal:  Mol Cell Endocrinol       Date:  2014-08-04       Impact factor: 4.102

Review 7.  Post-translational modification and regulation of actin.

Authors:  Jonathan R Terman; Anna Kashina
Journal:  Curr Opin Cell Biol       Date:  2012-11-27       Impact factor: 8.382

Review 8.  Rad54: the Swiss Army knife of homologous recombination?

Authors:  Wolf-Dietrich Heyer; Xuan Li; Michael Rolfsmeier; Xiao-Ping Zhang
Journal:  Nucleic Acids Res       Date:  2006-08-25       Impact factor: 16.971

9.  SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.

Authors:  Sophia X Pfister; Sara Ahrabi; Lykourgos-Panagiotis Zalmas; Sovan Sarkar; François Aymard; Csanád Z Bachrati; Thomas Helleday; Gaëlle Legube; Nicholas B La Thangue; Andrew C G Porter; Timothy C Humphrey
Journal:  Cell Rep       Date:  2014-06-12       Impact factor: 9.423

10.  Phenotypic transformation affects associative learning in the desert locust.

Authors:  Patrício M V Simões; Jeremy E Niven; Swidbert R Ott
Journal:  Curr Biol       Date:  2013-11-21       Impact factor: 10.834

View more
  4 in total

Review 1.  Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications.

Authors:  Daniel Desaulniers; Paule Vasseur; Abigail Jacobs; M Cecilia Aguila; Norman Ertych; Miriam N Jacobs
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

2.  Correlation Analysis of DNA Methylation in the von Willebrand Factor Promoter Region and the Risk of Unexplained Recurrent Hemophilia: Systematic Review and Meta-Analysis.

Authors:  Jing Dong; Jie Li; Ling Yang; Qiuhong Kong; Zhirong Zhang; Hong Zhang
Journal:  Contrast Media Mol Imaging       Date:  2022-06-03       Impact factor: 3.009

3.  Developmental Physiology: Grand Challenges.

Authors:  Warren Burggren
Journal:  Front Physiol       Date:  2021-06-10       Impact factor: 4.566

4.  The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

Authors:  Jean-Noël Hubert; Voreak Suybeng; Maxime Vallée; Tiffany M Delhomme; Eve Maubec; Anne Boland; Delphine Bacq; Jean-François Deleuze; Fanélie Jouenne; Paul Brennan; James D McKay; Marie-Françoise Avril; Brigitte Bressac-de Paillerets; Estelle Chanudet
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.